Reaction
Nasal Crusting reporting signals
As of the last recalculation, Nasal Crusting appears in 630 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is MOMETASONE FUROATE (PRR 52.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Mometasone Furoate | 60 | 52.5 | 52.5 |
| Umeclidinium | 6 | 22.3 | 22.4 |
| Erlotinib | 5 | 17.2 | 17.2 |
| Panitumumab | 7 | 14.9 | 14.9 |
| Acalabrutinib | 5 | 13.7 | 13.7 |
| Erlotinib Hydrochloride | 5 | 13.3 | 13.3 |
| Rimegepant Sulfate | 4 | 10.5 | 10.5 |
| Esketamine Hydrochloride | 5 | 9.3 | 9.3 |